NP137: Clinical Trials

3 trials of NP137, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 terminated. 3 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 2, Terminated 1
Phase 12Active not recruiting 1, Terminated 1

Follow NP137: new trials by email Literature Review of NP137 trials Research Report on NP137

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory
Phase 1 / Phase 2TerminatedCentre Leon Berard12024-09-112025-02-20
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
NP137, anti-PD-1/PD-L1 - Advanced Solid Tumors, Metastatic Solid Tumors
Phase 2Active not recruitingCentre Leon Berard572023-01-062026-09-25
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
NP137, Pembrolizumab, Paclitaxel - Endometrial Carcinoma, Cervix Carcinoma
Phase 1 / Phase 2Active not recruitingNETRIS Pharma2402020-12-142024-10-08

Conditions studied

Endometrial Neoplasms (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Centre Leon Berard (2)  ·  NETRIS Pharma (1)

Countries

France (3)